Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor-Reference-Cited by-同舟云学术

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor

Published:2018-06-11 Issue:8 Volume:38 Page:703-713
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Smith William B.^ORCID,Hall Jesse,Berg Jolene K.,Kazimir Michal,Yamamoto Amy,Walker Susan,Lee Caroline A.,Shen Zancong,Wilson David M.,Zhou Dongmei,Gillen Michael,Marbury Thomas C.

Funder

Ardea Biosciences/AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-018-0652-2/fulltext.html

Reference38 articles.

1. Pascual E, Andres M, Vela P. Gout treatment: should we aim for rapid crystal dissolution? Ann Rheum Dis. 2013;72(5):635–7.

2. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31–41.

3. Shiozawa A, Buysman EK, Korrer S. Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin. 2017;33(1):117–24.

4. Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;17:120.

5. Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174–83.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25

2. Recent advances in gout drugs;European Journal of Medicinal Chemistry;2023-01

3. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants;Pharmacology Research & Perspectives;2022-05-20

4. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications;European Journal of Pharmacology;2021-09

5. In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters;Journal of Pharmacology and Experimental Therapeutics;2021-06-01